» Articles » PMID: 29093755

Unique Amplification of BCR-ABL1 Gene Fusion in a Case of T-cell Acute Lymphoblastic Leukemia

Overview
Journal Mol Cytogenet
Publisher Biomed Central
Specialty Biochemistry
Date 2017 Nov 3
PMID 29093755
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Background: ABL1 gene translocations can be seen in precursor T-acute lymphoblastic leukemia (T-ALL). The typical translocation partner is the NUP214 gene. BCR-ABL translocations are relatively rare in this entity. Furthermore, while there have been unique patterns of amplification noted among the NUP214-ABL fusion genes, there have been few such reports among cases with BCR-ABL fusion genes.

Case Presentation: Here we report a unique case of a 44-year old patient with T-ALL in which the blasts demonstrated a derivative chromosome 9 involving a 9;22 translocation and a dicentric Philadelphia chromosome 22 with a homogeneously staining region at the interface of the 9;22 translocation, leading to BCR-ABL1 gene amplification. Fluorescence in-situ hybridization (FISH) showed abnormal BCR/ABL1 fusions with the BCR-ABL1 gene amplification in 48% of the interphase cells analyzed. The translocation was confirmed by SNP array.

Conclusions: We present a novel derivative chromosome 9 that shows BCR-ABL gene fusion along with a dicentric Philadelphia chromosome 22 with BCR-ABL1 gene amplification. This is a unique pattern of BCR-ABL fusion which has never been described in T-ALL. It is significant that the patient responded to standard treatment with the CALGB 10403 protocol and supplementation with a tyrosine kinase inhibitor. Identification of additional patients with this pattern of BCR-ABL fusion will allow for enhanced risk assessment and prognostication.

Citing Articles

Amplification of the Fusion Gene: A Rare Phenomenon in B-cell Acute Lymphoblastic Leukemia.

Ray D, Sharma P, Jain A, Sreedharanunni S Turk J Haematol. 2023; 40(3):204-205.

PMID: 37649438 PMC: 10476253. DOI: 10.4274/tjh.galenos.2023.2023.0212.


Case Report: A novel intergenic MIR4299/MIR8070-RET fusion with RET amplification and clinical response to pralsetinib in a lung adenocarcinoma patient.

Wang S, Wang F, Zeng Z, Gao F, Liu H, Wang H Front Oncol. 2022; 12:929763.

PMID: 36226049 PMC: 9548572. DOI: 10.3389/fonc.2022.929763.

References
1.
Deenik W, Beverloo H, van der Poel-van de Luytgaarde S, Wattel M, van Esser J, Valk P . Rapid complete cytogenetic remission after upfront dasatinib monotherapy in a patient with a NUP214-ABL1-positive T-cell acute lymphoblastic leukemia. Leukemia. 2008; 23(3):627-9. DOI: 10.1038/leu.2008.318. View

2.
Pui C, Campana D, Evans W . Childhood acute lymphoblastic leukaemia--current status and future perspectives. Lancet Oncol. 2002; 2(10):597-607. DOI: 10.1016/S1470-2045(01)00516-2. View

3.
van Rhee F, Hochhaus A, Lin F, Melo J, Goldman J, Cross N . p190 BCR-ABL mRNA is expressed at low levels in p210-positive chronic myeloid and acute lymphoblastic leukemias. Blood. 1996; 87(12):5213-7. View

4.
Fielding A, Rowe J, Buck G, Foroni L, Gerrard G, Litzow M . UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia. Blood. 2013; 123(6):843-50. PMC: 3916877. DOI: 10.1182/blood-2013-09-529008. View

5.
Graux C, Stevens-Kroef M, Lafage M, Dastugue N, Harrison C, Mugneret F . Heterogeneous patterns of amplification of the NUP214-ABL1 fusion gene in T-cell acute lymphoblastic leukemia. Leukemia. 2008; 23(1):125-33. DOI: 10.1038/leu.2008.278. View